New research reveals teclistamab and daratumumab significantly enhance progression-free survival in multiple myeloma, ...

Iberdomide and mezigdomide are currently being evaluated for the treatment of patients with multiple myeloma in a number of ...

The FDA has “proactively” granted Johnson & Johnson a coveted speedy review under the Commissioner’s National Priority ...

In this study, researchers aimed to determine whether patients with standard-risk relapsed/refractory multiple myeloma had improved survival with earlier-line cilta-cel therapy.

LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...

ASH Annual Meeting and Exposition leaves the oncology community buzzing over a series of late-breaking presentations that experts are calling 'unprecedented.' Major pharmaceutical developers such as ...

From 2017 to 2024, newly diagnosed multiple myeloma (MM) patients rapidly received quadruplet therapies over triplets, with ...

A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...

Gilead and Arcellx reported promising data for their CAR-T therapy anito-cel at the annual American Society of Hematology ...

Maintenance therapy is given after initial treatment for multiple myeloma. It aims to control your cancer and prevent progression. The type of maintenance therapy you receive depends on whether your ...

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have uncovered biological differences ...

Smoldering multiple myeloma (SMM) is a precancerous condition affecting white blood cells, called plasma cells, in the bone marrow. It can turn into multiple myeloma, a form of blood cancer that can ...